BeOne Medicines (NASDAQ:ONC) Director Alessandro Riva Sells 212 Shares

Posted by Stanley Muller on May 28th, 2026

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) Director Alessandro Riva sold 212 shares of the business’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $309.51, for a total transaction of $65,616.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Stock Performance

NASDAQ:ONC opened at $300.01 on Thursday. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. BeOne Medicines Ltd. – Sponsored ADR has a fifty-two week low of $235.57 and a fifty-two week high of $385.22. The stock has a market cap of $32.92 billion, a PE ratio of 67.12 and a beta of 0.50. The firm’s fifty day simple moving average is $301.85 and its 200-day simple moving average is $321.12.

BeOne Medicines (NASDAQ:ONC – Get Free Report) last posted its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The business had revenue of $1.51 billion for the quarter. Analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 5.65 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ONC. Barclays upped their price target on shares of BeOne Medicines from $405.00 to $409.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Jefferies Financial Group cut shares of BeOne Medicines from a “buy” rating to a “hold” rating and lowered their price target for the stock from $420.00 to $290.00 in a research note on Monday, March 16th. Morgan Stanley reaffirmed an “overweight” rating and set a $395.00 price target on shares of BeOne Medicines in a research note on Thursday, May 7th. Wall Street Zen raised shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, Wells Fargo & Company initiated coverage on shares of BeOne Medicines in a research report on Monday, May 4th. They issued an “overweight” rating and a $400.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $389.15.

View Our Latest Report on ONC

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ONC. Cetera Investment Advisers purchased a new position in BeOne Medicines in the 2nd quarter valued at about $455,000. Rhumbline Advisers purchased a new position in BeOne Medicines in the 2nd quarter valued at about $275,000. Arrowstreet Capital Limited Partnership purchased a new position in BeOne Medicines in the 2nd quarter valued at about $505,000. Invesco Ltd. purchased a new position in BeOne Medicines in the 2nd quarter valued at about $422,000. Finally, EverSource Wealth Advisors LLC purchased a new position in BeOne Medicines in the 2nd quarter valued at about $68,000. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

BeOne Medicines Company Profile

(Get Free Report)

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.